Invivoscribe is committed to providing high - quality
personalized molecular diagnostic testing.
Not exact matches
Although doctors have long incorporated personal information like family history into treatment plans,
personalized medicine holds the promise of revolutionizing medical care by using knowledge of
molecular biology and genetics that will allow more precise diagnoses, better
diagnostic tests, greater predictability of disease course, more successful therapies by targeting the right treatments to the right patients, and improved patient safety by selecting drugs and their proper dosage to reduce adverse side effects.
Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting - edge reagents,
tests, and bioinformatics tools to advance the fields of
personalized molecular diagnostics ® and
personalized molecular medicine.
SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker
testing solutions for the fields of oncology,
personalized molecular diagnostics ®, and
personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.
It is his mission to provide high quality, reliable, cutting - edge reagents,
tests, and bioinformatic tools to advance the fields of
personalized molecular diagnostics ® and
personalized molecular medicine ®.